Cansino Biologics Inc. — Investor Relations & Filings
About Cansino Biologics Inc.
CanSino Biologics Inc. is a biopharmaceutical company dedicated to the development, manufacturing, and commercialization of innovative vaccine products. The company utilizes four core technology platforms: adenovirus-based viral vector technology, protein structure design and recombinant technology, conjugation technology, and formulation technology. Its product portfolio includes Convidecia, a recombinant COVID-19 vaccine (Ad5-nCoV) available in both injectable and inhaled forms, and Menhyke and Menace, which are meningococcal conjugate vaccines. CanSino Biologics also advances a diverse pipeline targeting infectious diseases such as Ebola virus disease, pneumonia, and tuberculosis. By leveraging its integrated R&D and large-scale manufacturing capabilities, the company aims to provide high-quality, accessible vaccines to address global public health needs and emerging infectious disease threats.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 2025年度会计师事务所履职情况评估报告 | 2026-03-30 | Chinese | |
| 独立董事2025年度述职报告（张耀樑） | 2026-03-30 | Chinese | |
| 2025年环境、社会及管治（ESG）暨可持续发展报告 | 2026-03-30 | Chinese | |
| 2025年环境、社会及管治（ESG）暨可持续发展报告摘要 | 2026-03-30 | Chinese | |
| 中信证券股份有限公司关于康希诺生物股份公司2025年度募集资金存放、管理与实际使用情况的专项报告的核查意见 | 2026-03-30 | Chinese | |
| 关于开展外汇套期保值业务的公告 | 2026-03-30 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 39019731 | 2025年度会计师事务所履职情况评估报告 | 2026-03-30 | Chinese | ||
| 39019727 | 独立董事2025年度述职报告（张耀樑） | 2026-03-30 | Chinese | ||
| 39019716 | 2025年环境、社会及管治（ESG）暨可持续发展报告 | 2026-03-30 | Chinese | ||
| 39019581 | 2025年环境、社会及管治（ESG）暨可持续发展报告摘要 | 2026-03-30 | Chinese | ||
| 39019579 | 中信证券股份有限公司关于康希诺生物股份公司2025年度募集资金存放、管理与实际使用情况的专项报告的核查意见 | 2026-03-30 | Chinese | ||
| 39019567 | 关于开展外汇套期保值业务的公告 | 2026-03-30 | Chinese | ||
| 39019555 | 2025年年度报告 | 2026-03-30 | Chinese | ||
| 39019528 | 关于2023年A股员工持股计划存续期展期的公告 | 2026-03-30 | Chinese | ||
| 39019526 | 关于提请股东会授权董事会以简易程序向特定对象发行股票的公告 | 2026-03-30 | Chinese | ||
| 39019524 | 2025年年度报告摘要 | 2026-03-30 | Chinese | ||
| 39019508 | 董事会关于独立董事独立性自查情况的专项报告 | 2026-03-30 | Chinese | ||
| 39019505 | 中信证券股份有限公司关于康希诺生物股份公司部分募集资金投资项目延期的核查意见 | 2026-03-30 | Chinese | ||
| 39019493 | 审计委员会对2025年度会计师事务所履行监督职责情况报告 | 2026-03-30 | Chinese | ||
| 39019489 | 董事会审计委员会2025年度履职报告 | 2026-03-30 | Chinese | ||
| 39019475 | 未来三年（2026年-2028年）股东分红回报规划 | 2026-03-30 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
89bio, Inc.
Clinical-stage biopharma developing therapies for liver and…
|
ETNB | US | Manufacturing |
|
Aardvark Therapeutics, Inc.
Clinical-stage biopharma developing therapeutics for hunger…
|
AARD | US | Manufacturing |
|
Aarey Drugs & Pharmaceuticals Ltd
Manufactures APIs and chemical intermediates for global pha…
|
AAREYDRUGS | IN | Manufacturing |
|
Aarti Drugs Limited
Produces APIs, pharma intermediates, and specialty chemical…
|
AARTIDRUGS | IN | Manufacturing |
|
Aarti Pharmalabs Limited
Manufacturer of APIs, intermediates, and xanthines with glo…
|
AARTIPHARM | IN | Manufacturing |
|
AAYUSH WELLNESS LIMITED
Develops and markets herbal formulations, supplements, and …
|
539528 | IN | Manufacturing |
|
Ab&B Bio-Tech CO., LTD. JS
Biopharmaceutical company engaged in the R&D and commercial…
|
2627 | HK | Manufacturing |
|
Abbisko Cayman Limited
Clinical-stage biopharma focused on discovering and develop…
|
2256 | KY | Manufacturing |
|
Abbott India Ltd.
Provides pharmaceutical solutions in gastroenterology, card…
|
ABBOTINDIA | IN | Manufacturing |
|
ABBOTT LABORATORIES
Global healthcare company in medical devices, diagnostics, …
|
ABT | US | Manufacturing |
Cansino Biologics Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58218/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58218 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58218 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58218 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58218}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Cansino Biologics Inc. (id: 58218)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.